Impact of increased single-inhaler triple therapy use in appropriate patients on COPD exacerbations, mortality, and medical costs: PROMETHEUS Spain.
Marín-Oto, Marta (Universidad de Zaragoza) ; Mestre-Ferrándiz, Jorge ; Sánchez-Covisa, Joaquín ; Corregidor García, Carmen ; Martínez-Martínez, Néstor ; Bell, John ; Caplen, Melissa ; Bhatt, Prachi D. ; Carioto, Jennifer ; Pyenson, Bruce
Resumen: Introduction: COPD is the third cause of death in Spain. The ETHOS (NCT02465567) and IMPACT (NCT02164513) RCTs showed reduced exacerbations and all-cause mortality for single-inhaler triple therapy (SITT), but no studies have evaluated the potential impact on COPD outcomes of higher SITT adoption in Spain.
Methods: We used literature-based data on patient characteristics, incidence, COPD severity changes, treatment distributions/transitions, mortality, exacerbations, and medical costs, to inform a stochastic simulation of the Spanish COPD population for 2025-2034 under two scenarios: “Status Quo” and “Increased SITT”, in which higher SITT use is driven by airflow limitation, exacerbation history (as per 2025 GOLD guidelines) and SITT replacing multiple-inhaler triple therapy (MITT). Additionally, we present results separately for the subset of patients that met the criteria for SITT use, referred to as “flagged population.”
Results: In our 10-year simulation, increased SITT use in the flagged population could lead to 51,000 deaths avoided resulting in a 14.6% reduction in mortality rates and extended patient life by 1.2 years per COPD flagged patient. Additionally, increased SITT use in the flagged population reduced severe and moderate exacerbations by 62,000 (an 11.5% reduction) and 366,000 (an 11.6% reduction), respectively, resulting in total medical savings of €384 million.
Conclusion: Based on our simulation, increased use of SITT in the Spanish COPD population, consistent with the most recent 2025 GOLD guidelines’ recommendations, could reduce mortality and exacerbations and their corresponding medical costs. Increasing SITT utilization in patients with COPD may constitute a long-term strategy with relevant clinical and economic benefits.
Idioma: Inglés
DOI: 10.1159/000549626
Año: 2025
Publicado en: RESPIRATION (2025), 1-18
ISSN: 0025-7931
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial.
Exportado de SIDERAL (2026-01-12-11:08:59)
Visitas y descargas
Methods: We used literature-based data on patient characteristics, incidence, COPD severity changes, treatment distributions/transitions, mortality, exacerbations, and medical costs, to inform a stochastic simulation of the Spanish COPD population for 2025-2034 under two scenarios: “Status Quo” and “Increased SITT”, in which higher SITT use is driven by airflow limitation, exacerbation history (as per 2025 GOLD guidelines) and SITT replacing multiple-inhaler triple therapy (MITT). Additionally, we present results separately for the subset of patients that met the criteria for SITT use, referred to as “flagged population.”
Results: In our 10-year simulation, increased SITT use in the flagged population could lead to 51,000 deaths avoided resulting in a 14.6% reduction in mortality rates and extended patient life by 1.2 years per COPD flagged patient. Additionally, increased SITT use in the flagged population reduced severe and moderate exacerbations by 62,000 (an 11.5% reduction) and 366,000 (an 11.6% reduction), respectively, resulting in total medical savings of €384 million.
Conclusion: Based on our simulation, increased use of SITT in the Spanish COPD population, consistent with the most recent 2025 GOLD guidelines’ recommendations, could reduce mortality and exacerbations and their corresponding medical costs. Increasing SITT utilization in patients with COPD may constitute a long-term strategy with relevant clinical and economic benefits.
Idioma: Inglés
DOI: 10.1159/000549626
Año: 2025
Publicado en: RESPIRATION (2025), 1-18
ISSN: 0025-7931
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial.Exportado de SIDERAL (2026-01-12-11:08:59)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos > Artículos por área > Medicina
Registro creado el 2026-01-12, última modificación el 2026-01-12